Sara Mirali

Sara Mirali

Auto-generated profile, based on publicly available information

Sara Mirali

Division of Dermatology, Department of Medicine University of Toronto Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2021 in Blood
Verified
Journal Article
Open access
PDF file
JLJong Bok Lee
Jong Bok Lee
DKDilshad H. Khan
Dilshad H. Khan
RHRose Hurren
Rose Hurren
MXMingjing Xu
Mingjing Xu
YNYoosu Na
Yoosu Na
ASAaron Schimmer
Aaron Schimmer
Venetoclax, a Bcl-2 inhibitor, in combination with the hypomethylating agent azacytidine, achieves complete remission with or without count recovery in ∼70% of treatment-naive elderly patients unfit for conventional intensive chemotherapy. However, the mechanism of action of this drug combination is not fully understood. We discovered that venetoclax directly activated T cells to increase their cytotoxicity against acute myeloid leukemia (AML) in vitro and in vivo. Venetoclax enhanced T-cell effector function by increasing reactive oxygen species generation through inhibition of respiratory chain supercomplexes formation. In addition, azacytidine induced a viral mimicry response in AML cells by activating the STING/cGAS pathway, thereby rendering the AML cells more susceptible to T cell–mediated cytotoxicity. Similar findings were seen in patients treated with venetoclax, as this treatment increased reactive oxygen species generation and activated T cells. Collectively, this study presents a new immune-mediated mechanism of action for venetoclax and azacytidine in the treatment of AML and highlights a potential combination of venetoclax and adoptive cell therapy for patients with AML.

8 April 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SMSara Mirali
Sara Mirali
ABAaron Botham
Aaron Botham
VVVeronique Voisin
Veronique Voisin
CXChangjiang Xu
Changjiang Xu
JSJonathan St-Germain
Jonathan St-Germain
ASAaron Schimmer
Aaron Schimmer
Targeting mitochondrial supercomplex assembly impairs metabolism and selectively targets leukemic cells.

5 August 2020 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
SMSara Mirali
Sara Mirali
ASAaron Schimmer
Aaron Schimmer
The biological function of most mitochondrial proteases has not been well characterized. Moreover, most of the available information on the normal function of these proteases has been derived from studies in model organisms. Recently, the mitochondrial proteases caseinolytic protease P (CLPP) and neurolysin (NLN) have been identified as therapeutic targets in acute myeloid leukemia (AML). Both proteases are overexpressed in approximately 40% of AML patients. Mechanistically, CLPP and NLN maintain the integrity of the mitochondrial respiratory chain: CLPP cleaves defective respiratory chain proteins, while NLN promotes the formation of respiratory chain supercomplexes. In this review, we highlight the functional consequences of inhibiting and activating mitochondrial proteases and discuss their potential as therapeutic targets in AML. Significance statement Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Despite recent advances and new therapies for this disease, the prognosis for most patients with AML remains poor. Understanding the biology of this disease is important for developing new therapies. Recently, AML cells and stem cells have been shown to have unique mitochondrial properties, which can be therapeutically targeted. One of these properties is an increased reliance on the mitochondrial matrix proteases, caseinolytic protease P and neurolysin. This perspective discusses the effects of genetically and chemically dysregulating mitochondrial proteases in AML. Moreover, this study considers the potential of targeting mitochondrial proteases as a novel therapeutic strategy.

20 August 2025 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
SMSara Mirali
Sara Mirali
ADAaron M. Drucker
Aaron M. Drucker
Atopic dermatitis is an inflammatory skin condition characterised by pruritus and a chronic relapsing–remitting course. Previous topical and systemic treatments for atopic dermatitis were broadly immunosuppressive, which limited their long‐term use. Recently, more targeted therapies for atopic dermatitis have been developed. In this review, we discuss the efficacy and safety of new therapies, including topical PDE4 (phosphodiesterase 4) inhibitors, a topical aryl hydrocarbon receptor agonist, topical and systemic JAK (Janus kinase) inhibitors and biologics.

28 March 2021 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Open access
PDF file
SMSara Mirali
Sara Mirali
AAAbrahim Abduelmula
Abrahim Abduelmula
AMAsfandyar Mufti
Asfandyar Mufti
MSMuskaan Sachdeva
Muskaan Sachdeva
JYJensen Yeung
Jensen Yeung
Palmoplantar keratoderma (PPK) are a heterogenous group of hereditary and acquired disorders that are characterized by excessive epidermal thickening of the palms and/or soles. PPK has been described as a rare adverse event for some medications. The aim of this systematic review was to summarize outcomes in PPK associated with various medications. This data will assist dermatologists and other healthcare providers treating patients with drug-induced PPK. EMBASE and MEDLINE databases were searched in accordance with PRISMA guidelines using the keyword “palmoplantar keratoderma.” 40 studies met the inclusion criteria. A total of 247 patients (mean age: 57.0 years) were included in the analysis. Among patients whose sex was reported, 60.3% (n = 35/58) were male. PPK most frequently developed after treatment with BRAF inhibitors (73.7%, n = 182/247), BRAF inhibitors combined with MEK1/2 inhibitors (15.4%, n = 38/247), tyrosine kinase inhibitors (TKIs) (3.2%, n = 8/247), or chemotherapy (2.4%, n = 6/247). The mean latency period between initiation of the drug and onset of PPK was 7.6 months (range: 0.25-90 months). Improvement of PPK was reported in 24 cases, with 50% (n = 12/24) achieving complete resolution and 50% (n = 12/24) achieving partial resolution. All patients who achieved complete resolution stopped the suspected drug, with a mean resolution period of 2.4 months (range: 2 weeks-6 months). The most common treatments for PPK were keratolytic treatments (n = 10) and topical corticosteroids (n = 4). PPK was most frequently associated with targeted kinase inhibitors, specifically BRAF, MEK1/2, and tyrosine kinase inhibitors.

28 November 2021 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Open access
PDF file
SMSara Mirali
Sara Mirali
AMAsfandyar Mufti
Asfandyar Mufti
RLRafael Paolo Lansang
Rafael Paolo Lansang
MSMuskaan Sachdeva
Muskaan Sachdeva
JYJensen Yeung
Jensen Yeung
Eruptive seborrheic keratoses (ESK) is a benign skin condition that has been associated with malignant and nonmalignant diseases. We conducted a systematic review of reported cases of ESK to identify and summarize associated comorbidities. MEDLINE and Embase were searched from database inception (1946) to July 31, 2020 for original articles describing ESK with or without a co-occurring condition. Subject demographics, as well as details of ESK and associated diagnoses were extracted from 76 articles (70 case reports, 3 case series, 3 case control studies) representing 92 patients. In total, 76.1% (n = 70/92) of patients with ESK had a co-occurring malignancy, 4.3% (n = 4/92) presented with a nonmalignant condition, 9.8% (n = 9/92) experienced ESK as an adverse drug reaction, and 9.8% (n = 9/92) did not report any underlying medical condition. ESK preceded a cancer diagnosis in 76.1% (n = 70/92) of patients with a mean latency period of 4.0 months (range: 0.25-9 months). The most common malignancies associated with ESK were cutaneous T-cell lymphoma (n = 10/70, 14.3%) and gastrointestinal adenocarcinoma (n = 9/70, 12.9%). ESK preceded nonmalignant conditions or no disease in 14.1% (n = 13/92) of patients with a mean latency period of 3.1 months (range: 0.75-6 months). Drug-induced ESK occurred in 9.8% (n = 9/92) of patients with a mean latency period of 7.1 weeks after changing medication. Although the role of ESK as a paraneoplastic cutaneous marker is debated, healthcare providers should consider screening for underlying malignancy in patients presenting with ESK. Larger studies are needed to confirm its role as a marker for disease.